Marco Insights delivers governments, pharmaceutical companies and public health organizations aggregated, anonymized data on consultation patterns, diagnostic challenges and recurring therapeutic questions in Non-Melanoma Skin Cancer across countries and regions. The insights enable evidence-based policy, investment and therapeutic strategies.
Some answers to questions we often receive
Marco Insights aggregates anonymized data on Non-Melanoma Skin Cancer consultation frequency, distribution of molecular subtypes queried, treatment-by-line question patterns, regions with highest diagnostic uncertainty and gaps between local practice and NCCN/ESMO guidelines, updatable in real time by country.
Yes. Marco Insights automatically cross-references Non-Melanoma Skin Cancer physician query patterns with current guideline recommendations, identifying areas where clinical practice deviates from standard: molecular underdiagnosis, suboptimal biomarker use or underutilization of targeted therapies with clear indication.
Marco Insights updates in real time with every new Marco system interaction on Non-Melanoma Skin Cancer. Dashboards reflect data from the selected period (week, month, quarter), enabling detection of emerging trends such as the impact of a new regulatory approval or published guideline.
Marco Insights lets pharma companies understand real-world penetration of their products in Non-Melanoma Skin Cancer, identify the most frequent physician questions about their molecules, detect adoption barriers by region or institution type, and orient medical and access programs based on actual market needs.
Marco Insights dashboards can be segmented by country, region, institution type (public hospital, private clinic, primary care) and medical specialty, allowing governments and pharma to compare Non-Melanoma Skin Cancer management across different healthcare contexts and prioritize interventions.
Marco Insights works exclusively with aggregated, anonymized data. No data allows identification of individual patients, institutions or specific physicians without consent. The system complies with applicable data protection regulations and provides data processing agreements for each client.
Recent immunotherapy approvals in cutaneous carcinoma outpace available data on their real-world adoption in dermatology.